153 related articles for article (PubMed ID: 38813229)
1. T cell-mediated tumor killing based signature to predict the prognosis and immunotherapy for glioblastoma.
Liu H; Shi K; Wei Z; Zhang Y; Li J
Heliyon; 2024 May; 10(10):e31207. PubMed ID: 38813229
[TBL] [Abstract][Full Text] [Related]
2. TGF-β based risk model to predict the prognosis and immune features in glioblastoma.
Liu H; Wei Z; Zhang Y; Shi K; Li J
Front Neurol; 2023; 14():1188383. PubMed ID: 37456651
[TBL] [Abstract][Full Text] [Related]
3. Molecular Characteristics of T Cell-Mediated Tumor Killing in Hepatocellular Carcinoma.
Hong WF; Liu MY; Liang L; Zhang Y; Li ZJ; Han K; Du SS; Chen YJ; Ma LH
Front Immunol; 2022; 13():868480. PubMed ID: 35572523
[TBL] [Abstract][Full Text] [Related]
4. Pyroptosis-related prognosis model, immunocyte infiltration characterization, and competing endogenous RNA network of glioblastoma.
Ding MR; Qu YJ; Peng X; Chen JF; Zhang MX; Zhang T; Hu B; An HM
BMC Cancer; 2022 Jun; 22(1):611. PubMed ID: 35658846
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value and immune relevancy of a combined autophagy-, apoptosis- and necrosis-related gene signature in glioblastoma.
Bi Y; Wu ZH; Cao F
BMC Cancer; 2022 Mar; 22(1):233. PubMed ID: 35241019
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Benefits and Prognostic Value of a Model Based on 7 Immune-associated Genes in Bladder Cancer.
Cao M; Cao Y; Xue S; Zhang Q; Zhang H; Xue W
Altern Ther Health Med; 2024 Apr; 30(4):130-138. PubMed ID: 38518167
[TBL] [Abstract][Full Text] [Related]
7. Integrative transcriptional characterization of cell cycle checkpoint genes promotes clinical management and precision medicine in bladder carcinoma.
Shi WW; Guan JZ; Long YP; Song Q; Xiong Q; Qin BY; Ma ZQ; Hu Y; Yang B
Front Oncol; 2022; 12():915662. PubMed ID: 36033441
[TBL] [Abstract][Full Text] [Related]
8. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
Front Genet; 2022; 13():919389. PubMed ID: 35783281
[No Abstract] [Full Text] [Related]
9. Development and validation a prognostic model based on natural killer T cells marker genes for predicting prognosis and characterizing immune status in glioblastoma through integrated analysis of single-cell and bulk RNA sequencing.
Hu J; Xu L; Fu W; Sun Y; Wang N; Zhang J; Yang C; Zhang X; Zhou Y; Wang R; Zhang H; Mou R; Du X; Li X; Hu S; Xie R
Funct Integr Genomics; 2023 Aug; 23(3):286. PubMed ID: 37650991
[TBL] [Abstract][Full Text] [Related]
10. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
11. Co-expression prognostic-related genes signature base on propofol and sevoflurane anesthesia predict prognosis and immunotherapy response in glioblastoma.
Hou Z; Luo D; Luo H; Hui Q; Xu Y; Lin X; Xu Z
Ann Med; 2023 Dec; 55(1):778-792. PubMed ID: 36856519
[TBL] [Abstract][Full Text] [Related]
12. Development and Validation of a Prognostic Gene Signature Correlated With M2 Macrophage Infiltration in Esophageal Squamous Cell Carcinoma.
Yao J; Duan L; Huang X; Liu J; Fan X; Xiao Z; Yan R; Liu H; An G; Hu B; Ge Y
Front Oncol; 2021; 11():769727. PubMed ID: 34926275
[TBL] [Abstract][Full Text] [Related]
13. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
[TBL] [Abstract][Full Text] [Related]
14. The Landscape of the Tumor Microenvironment in Skin Cutaneous Melanoma Reveals a Prognostic and Immunotherapeutically Relevant Gene Signature.
Zhou S; Sun Y; Chen T; Wang J; He J; Lyu J; Shen Y; Chen X; Yang R
Front Cell Dev Biol; 2021; 9():739594. PubMed ID: 34660598
[TBL] [Abstract][Full Text] [Related]
15. Identification and validation of a novel senescence-related biomarker for thyroid cancer to predict the prognosis and immunotherapy.
Hong K; Cen K; Chen Q; Dai Y; Mai Y; Guo Y
Front Immunol; 2023; 14():1128390. PubMed ID: 36761753
[TBL] [Abstract][Full Text] [Related]
16. Tumor immune microenvironment-based clusters in predicting prognosis and guiding immunotherapy in breast cancer.
Liu Y; He X; Yang YI
J Biosci; 2024; 49():. PubMed ID: 38287674
[TBL] [Abstract][Full Text] [Related]
17. Identification of Hypoxia Prognostic Signature in Glioblastoma Multiforme Based on Bulk and Single-Cell RNA-Seq.
Ahmed YB; Ababneh OE; Al-Khalili AA; Serhan A; Hatamleh Z; Ghammaz O; Alkhaldi M; Alomari S
Cancers (Basel); 2024 Feb; 16(3):. PubMed ID: 38339384
[TBL] [Abstract][Full Text] [Related]
18. Systematic analysis based on the cuproptosis-related genes identifies ferredoxin 1 as an immune regulator and therapeutic target for glioblastoma.
Dai L; Zhou P; Lyu L; Jiang S
BMC Cancer; 2023 Dec; 23(1):1249. PubMed ID: 38114959
[TBL] [Abstract][Full Text] [Related]
19. Identification of prognostic gene signature associated with microenvironment of lung adenocarcinoma.
Yue C; Ma H; Zhou Y
PeerJ; 2019; 7():e8128. PubMed ID: 31803536
[TBL] [Abstract][Full Text] [Related]
20. Immune-related lncRNAs signature and radiomics signature predict the prognosis and immune microenvironment of glioblastoma multiforme.
Luan J; Zhang D; Liu B; Yang A; Lv K; Hu P; Yu H; Shmuel A; Zhang C; Ma G
J Transl Med; 2024 Jan; 22(1):107. PubMed ID: 38279111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
